Skip to Main Content

Author Details

Justin Cidado
Oncology R&D
2003
31
19
PMIDPaper TitleJournal TitlePublished Year
37380821A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models.AAPS J2023
33353284Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.Haematologica2022
33259592Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.Blood2021
33495510Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy.Commun Biol2021
34050131A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.Cell Death Discov2021
32988967AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.Clin Cancer Res2020
31699827AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.Clin Cancer Res2020
33306391Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.J Med Chem2020
30498064Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.Blood2019
31727958Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies.Nat Commun2019
31243099Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.Mol Cancer Ther2019
31294695The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells.Elife2019
30816329BCL2 blockade overcomes MCL1 resistance in multiple myeloma.Leukemia2019
29266803Structure-Based Design of Selective Noncovalent CDK12 Inhibitors.ChemMedChem2018
28190247PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.Breast Cancer Res Treat2017
26823390Ki-67 is required for maintenance of cancer stem cells but not cell proliferation.Oncotarget2016
26261103ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.Clin Cancer Res2016
25367220A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.Proteomics2015
26324937NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability.Proc Natl Acad Sci U S A2015
26246475Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.Oncotarget2015
26508629HER2 missense mutations have distinct effects on oncogenic signaling and migration.Proc Natl Acad Sci U S A2015
26702755TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer.Oncotarget2015
24504125Detection of cancer DNA in plasma of patients with early-stage breast cancer.Clin Cancer Res2014
25422431MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.Proc Natl Acad Sci U S A2014
24824029Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction.Hum Pathol2014
23580570Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.Cancer Res2013
23425423Needles in a haystack: finding recurrent genomic changes in breast cancer.Breast Cancer Res2013
22865098Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.J Mammary Gland Biol Neoplasia2012
21124076PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.Cancer Biol Ther2011
21987798Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.Proc Natl Acad Sci U S A2011
14688527Analysis of cytokine functions in graft rejection by gene expression profiles.Transplantation2003
  • 1 - 31 of 31

Recommended Authors

Gray R Anderson
Duke University
Career Start Year 2014
Number of shared co-authors 0
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Stuart J Blakemore
Center for Molecular Medicine Cologne (CMMC), University of Cologne
Career Start Year 2010
Number of shared co-authors 0
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 2
Janet Pittsenbarger
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 2
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 4
Rut Klinger
UCD Conway Institute, University College Dublin
Career Start Year 2006
Number of shared co-authors 0
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 0
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 2
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 1
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 1
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 2
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2002
Number of shared co-authors 4
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 1
Nikhil Wagle
Dana-Farber Cancer Institute
Career Start Year 2000
Number of shared co-authors 5
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 2
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 1
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 3
Andrei Goga
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 0
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 3
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 4
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 2
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 4
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 3
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 12
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 2

Collaborators

Ben Ho Park
Vanderbilt University Medical Center
Co-authored papers 16
Julia A Beaver
Center for Drug Evaluation and Research
Co-authored papers 10
Pedram Argani
The Johns Hopkins Hospital
Co-authored papers 7
Stephen Fawell
Oncology R&D
Co-authored papers 4
Jamal C Saeh
Oncology R&D
Co-authored papers 4
Shenghua Wen
Oncology R&D
Co-authored papers 3
J Paul Secrist
Oncology R&D
Co-authored papers 3
Jeffrey G Varnes
Oncology R&D
Co-authored papers 3
Alwin G Schuller
Oncology R&D
Co-authored papers 3
Nancy Su
Co-authored papers 3
Gareth P Gregory
School of Clinical Sciences at Monash Health, Monash University
Co-authored papers 2
Ammar Adam
Oncology R&D
Co-authored papers 2
Francis D Gibbons
Preclinical and Translational Sciences, Inc.
Co-authored papers 2
Barry R Davies
Oncology R&D
Co-authored papers 2
Eric Gangl
Oncology R&D
Co-authored papers 2
Ricky W Johnstone
The University of Melbourne
Co-authored papers 2
Edward J Hennessy
Oncology R&D
Co-authored papers 2
Steven W Criscione
Oncology R&D
Co-authored papers 2
David M Weinstock
Merck & Co.
Co-authored papers 2
Martin Wild
Oncology R&D
Co-authored papers 2
Michael Zinda
Repare Therapeutics Inc.
Co-authored papers 2
William McCoull
Oncology R&D
Co-authored papers 2
Jacob E Corn
Co-authored papers 1
John M Mariadason
Olivia Newton-John Cancer Research Institute
Co-authored papers 1
Deborah Lawson
Oncology R&D
Co-authored papers 1
Marzena Walkiewicz
Olivia Newton-John Cancer Research Institute
Co-authored papers 1
Vered Stearns
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Patricia Jaaks
Wellcome Sanger Institute
Co-authored papers 1
Xiahui Zhu
Co-authored papers 1
Release 1.2